Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enric Monreal

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|July 29, 2021
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple SclerosisCarmen Picón, Amalia Tejeda-Velarde, José Ignacio Fernández-Velasco, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 7, 2021
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MSJosé I Fernández-Velasco, Jens Kuhle, Enric Monreal, et al.
Multiple Sclerosis and Related Disorders|February 12, 2022
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosisSusana Sainz de la Maza, Julia Sabin Muñoz, Belén Pilo de la Fuente, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 24, 2024
Association of Complement Factors With Disability Progression in Primary Progressive Multiple SclerosisJan D Lunemann, Harald Hegen, Luisa María Villar, et al.
Journal of Neurology|December 12, 2024
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosisManuel Comabella, Harald Hegen, Luisa M Villar, et al.
International Journal of Molecular Sciences|July 29, 2025
Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple SclerosisEnric Monreal, José Ignacio Fernández-Velasco, Susana Sainz de la Maza, et al.
JAMA Neurology|February 27, 2023
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy DrugsEnric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2023
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosisNicolás Fissolo, Pascal Benkert, Jaume Sastre-Garriga, et al.
Frontiers in Immunology|April 7, 2022
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis PathologyJosé I Fernández-Velasco, Enric Monreal, Jens Kuhle, et al.
European Journal of Neurology|June 21, 2021
Risk and outcomes of COVID-19 in patients with multiple sclerosisIrene Moreno-Torres, Virginia Meca Lallana, Lucienne Costa-Frossard, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|July 29, 2021
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple SclerosisCarmen Picón, Amalia Tejeda-Velarde, José Ignacio Fernández-Velasco, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 7, 2021
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MSJosé I Fernández-Velasco, Jens Kuhle, Enric Monreal, et al.
Multiple Sclerosis and Related Disorders|February 12, 2022
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosisSusana Sainz de la Maza, Julia Sabin Muñoz, Belén Pilo de la Fuente, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 24, 2024
Association of Complement Factors With Disability Progression in Primary Progressive Multiple SclerosisJan D Lunemann, Harald Hegen, Luisa María Villar, et al.
Journal of Neurology|December 12, 2024
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosisManuel Comabella, Harald Hegen, Luisa M Villar, et al.
International Journal of Molecular Sciences|July 29, 2025
Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple SclerosisEnric Monreal, José Ignacio Fernández-Velasco, Susana Sainz de la Maza, et al.
JAMA Neurology|February 27, 2023
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy DrugsEnric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2023
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosisNicolás Fissolo, Pascal Benkert, Jaume Sastre-Garriga, et al.
Frontiers in Immunology|April 7, 2022
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis PathologyJosé I Fernández-Velasco, Enric Monreal, Jens Kuhle, et al.
European Journal of Neurology|June 21, 2021
Risk and outcomes of COVID-19 in patients with multiple sclerosisIrene Moreno-Torres, Virginia Meca Lallana, Lucienne Costa-Frossard, et al.
Pageof 6